New data do not SUPPORT triple RAAS blockade

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and beta-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin-aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.
Original languageUndefined/Unknown
Pages (from-to)260-261
Number of pages2
JournalNature Reviews Nephrology
Issue number5
Publication statusPublished - 2015

Cite this